Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler’s Chief Market ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

NovoCare Pharmacy offers cash-paying patients the ability to schedule shipments of Wegovy directly to their home, guaranteeing individuals receive the authentic FDA-approved product.

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from the tariff wars, Maggie Fick of ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ... president of Novo Nordisk Inc., said in a statement Friday.

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.